Status:
COMPLETED
Pomegranate Extract Supplementation in Colorectal Cancer Patients
Lead Sponsor:
National Research Council, Spain
Collaborating Sponsors:
Hospital Universitario Reina Sofia de Cordoba
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The most relevant pomegranate phenolics (ellagitannins and ellagic acid) are extensively metabolized by the human gut microbiota to yield a number of metabolites called urolithins (mainly Uro-A). Urol...
Eligibility Criteria
Inclusion
- Colorectal cancer diagnosis.
- Surgery required.
- WHO status: between 0 and 2.
- Hemoglobin \>10 g/dL
- ALT \>2.5-fold above the normal value.
- Serum Bilirubin \>1.5-fold above the normal value.
- Creatinine \<140 micromol/L
Exclusion
- Patients who do not satisfy inclusion criteria and,
- Active pectic ulcer.
- Pregnancy or breastfeeding.
- Alcoholism.
- Chemotherapy or radiotherapy a month prior to recruitment.
- Treatment with steroids or other anti-inflammatory drugs a week prior to recruitment.
Key Trial Info
Start Date :
June 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2015
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01916239
Start Date
June 1 2012
End Date
April 1 2015
Last Update
April 14 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital General Universitario Reina Sofía
Murcia, Murcia, Spain, 30003